Genexine Receives Approval for Phase 1/2a Clinical Trial of COVID-19 DNA Vaccine 'GX-19'

[Asia Economy Reporter Kim Heung-soon] Genexine announced on the 11th that it has received approval from the Ministry of Food and Drug Safety for the Phase 1/2a clinical trial of its COVID-19 vaccine candidate 'GX-19.'

Genexine plans to conduct a Phase 1 clinical trial by administering two different doses of the candidate to 40 healthy adults, followed by a Phase 2a trial in which one dose will be given to a total of 150 participants to evaluate safety and antibody formation efficacy.

GX-19 is a COVID-19 DNA vaccine developed by a consortium formed in March, consisting of Genexine, Vinex, the International Vaccine Institute (IVI), Genenbio, KAIST, and POSTECH.

Unlike traditional vaccines that inject weakened viruses into the body, DNA vaccines induce an immune response by administering genes that produce viral antigens into the human body. This method involves injecting recombinant DNA that produces proteins found on the surface of the COVID-19 virus into the body.

Genexine plans to complete the Phase 1 clinical trial within the next three months. In the second half of this year, it intends to conduct multinational Phase 2 clinical trials targeting not only South Korea but also countries severely affected by the COVID-19 pandemic.

This content was produced with the assistance of AI translation services.